Geisinger Medical Center is First in Pennsylvania to Treat Cancer Patients with Accuray Radixact® System

SUNNYVALE, Calif., Sept. 10, 2019 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Geisinger Medical Center radiation oncology team is first in Pennsylvania to treat cancer patients with the innovative Radixact^® System. The hospital, located in Danville, is part of Geisinger Health System, one of the United States' most innovative health services organizations. The system's speed, versatility and flexibility will enable the clinical team to provide a treatment option for virtually any case for which radiation therapy is prescribed, including large tumors or multiple tumors throughout the body, hard-to-reach tumors, and tumors that have recurred, including those in patients who may not be candidates for retreatment with traditional delivery systems.

Geisinger welcomed the Radixact System in a ribbon-cutting ceremony led by the chairman of radiation oncology at Geisinger Cancer Institute, Dr. Anand Mahadevan. "The Radixact System will enable us to treat patients with precision, speed and adaptability. The system's unique architecture provides options for delivering radiation not available with other devices and when combined with its advanced software, will expand the types of tumors that may be effectively treated with radiation, including craniospinal and total body radiation with comfort and precision," said Dr. Mahadevan. "We look forward to using the Radixact System to deliver the highest standard of care to patients in central Pennsylvania and the surrounding area."

According to the Centers for Disease Control and Prevention¹, the state of Pennsylvania had the third highest incidence rate of new cancers in the United States in 2016, the most current year data were reported. While the rate of new cancers diagnosed in the state remained relatively stable between 2012 - 2016¹, the data reinforce the need for innovative new treatment options that successfully manage the disease while minimizing side effects and their impact on quality of life.

The Radixact System was designed to improve patient care by providing clinical teams with the tools they need to make the planning and delivery of radiation straightforward, efficient and effective for standard indications like breast and head and neck cancers, and complex treatments such as total marrow irradiation.

• The Radixact System delivers the same highly conformal and homogeneous dose distribution faster than the previous TomoTherapy platform, with a higher dose rate (1000 MU/minute) and imaging time that is up to 66 percent faster. A combination of higher dose output and faster image acquisition can shorten treatment times, while improving the patient experience
• A fully-integrated, automated adaptive solution, PreciseART^® Adaptive Radiation Therapy Software, makes adaptive radiotherapy simple and practical. The software enables physicians to easily decide when adaptation of radiation delivery during the course of treatment would be beneficial due to changes in tumor size and patient anatomy
• The PreciseRTX^® Retreatment Option accelerates and automates the re-planning process to make re-treatment more efficient for practices and more effective for patients in those cases where, unfortunately, cancer has recurred and additional radiation treatments are necessary
• The CTrue™ IR (Iterative Reconstruction) image guidance software improves soft-tissue contrast and reduces noise, enhancing image quality, while maintaining the same low imaging dose and fast reconstruction time as earlier versions of the software. Patient workflows are also more streamlined, facilitating the delivery of precise treatments more quickly, for more patients

"We are excited to partner with the Geisinger Medical Center team to help improve the lives of patients diagnosed with cancer," said Birgit Fleurent, chief marketing officer at Accuray. "The Radixact System is intended to administer radiation using a variety of delivery methods from image-guided, intensity-modulated radiation therapy, TomoHelical™ rotational delivery mode and stereotactic body radiation therapy, to TomoDirect™ non-rotational delivery mode and TomoEDGE™ dynamic dose sculpting mode. This versatility provides the hospital's clinical team with unprecedented flexibility and choice, enabling them to offer a personalized and precise treatment approach that truly addresses each patient's particular condition."

Important Safety Information 
For Important Safety Information please refer to https://www.accuray.com/safety-statement.

About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and sells radiotherapy systems that are intended to make cancer treatments shorter, safer, personalized and more effective, ultimately enabling patients to live longer, better lives. Our radiation treatment delivery systems in combination with fully-integrated software solutions set the industry standard for precision and cover the full range of radiation therapy and radiosurgery procedures. For more information, please visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter and YouTube.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical experiences and results, patient experiences, and patient outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products; the company's ability to develop new products or improve existing products to meet customers' needs; the company's limited long-term clinical data supporting the safety and efficacy of its products and such other risks identified under the heading "Risk Factors" in the company's annual report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 23, 2019 and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Media Contacts
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426 
[email protected]

Jayme Maniatis
MSLGROUP 
+1 (781) 684-6610 
[email protected]

^{______________________________________
1} U.S. Cancer Statistics Working Group. U.S. Cancer Statistics Data Visualizations Tool, based on November 2018 submission data (1999-2016): U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; www.cdc.gov/cancer/dataviz, June 2019

SOURCE Accuray Incorporated

Related Links

http://www.accuray.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED